Market News
Smart Trading. Simplified.
Free 30-Day Access To Expert Trading System
Our friends at GorillaTrades are offering all readers the opportunity to get Free 30-day access to their Stock Picks, Options Picks, and Newsletters. There is NO credit card required to sign up, all you need is your name and email address to try the Gorilla's risk-averse trading system for the next 30 days. Get the edge you've been looking for, and try it today for free!
Click Here For Instant Access To Explosive Stock & Options Picks
Sponsored
Abiomed Vs Medtronic Stock: Which Is Best?
Abiomed Vs Medtronic Stock: The medical equipment industry is massive, encompassing anything used in the diagnosis, monitoring, or treatment of medical conditions. Tongue depressors and bedpans may be the simplest examples of medical equipment, but that’s just the beginning. CT scanners, MRIs, and ultrasound machines qualify under this heading, as do life-sustaining devices like ventilators […]
My #1 Small Cap Stock for January
Ex-Wall Street CEO Dylan Jovine has racked up big gains in small caps stocks. He's had three picks jump 100%, 111% and 171% just in the past 90 days!
Sponsored
Is Amphenol Stock A Buy?
Amphenol Corporation (NYSE:APH) is a fiber optic producer with applications for military, industrial, aerospace, and automotive industries. Its biggest revenue source can be found in the the race to 5G though. Data providers are rushing to lay high-speed fiber optics to run both landline and mobile broadband. Fiber optics has proven its value, which means […]
Market Creates Buying Opportunity in Company Set to Revolutionize Marijuana
A industry breakthrough discovery has positioned a little-known biotech to become the marijuana industry's "gatekeeper"... deciding who gets to play, and who doesn't. At the end of 2019, this stock was a "top pick." Today... Investors who take action before the imminent market rebound could turn every $1,000 into $156,445 within weeks.
Sponsored
Is Rocket Pharma Stock A Good Buy?
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) is a New York City-based biotechnology company focused on developing gene-modified cell therapies to combat a variety of diseases. Its pipeline includes treatments for Danon Disease, Fanconi Anemia, Leuokocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Infantile Malignant Osteopetrosis, many of which are in late-stage clinical trials. Many of its products are […]
The Small Cap that Could Pay Off Your Mortgage
Ex-Wall Street CEO Dylan Jovine has racked up big gains in small caps stocks. He's had three picks jump 100%, 111% and 171% just in the past 90 days!
But he thinks his next pick has the potential to pay off your house >>>
Sponsored
Is APD A Good Stock To Buy?
Air Products & Chemicals, Inc. (NYSE:APD) is an industrial gas and chemical company based in Pennsylvania but with a global client base. The company has a long and tenured history; it was founded in 1940. As the market deflated, APD stock fell too. But the company quickly rebounded from the initial market crisis to reach […]
New 5G "Arrow" to Replace Nuclear Missiles
On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The New York Times reports "No existing defense can stop it." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $461,800 >>>
Sponsored
Is GoodRx Stock A Buy?
Is GoodRx Stock A Buy? Telemedicine’s rising popularity has been spurred by the global pandemic. Talk about a sizzling investment space! For instance, consider Teladoc (TDOC) – the company’s stock has skyrocketed by almost 170% in 2020. While patients and their physicians adapt to a virtual world of interactions, the healthcare industry is desperately seeking […]
My #1 5G Takeover Target forJanuary
Ex-Wall Street CEO Dylan Jovine is the best takeover investor on earth. On August 6, 2020, he recommended Denali... 60 days later it was up 110% on news of its Biogen deal. On May 8, 2020, he recommended Agio Pharmaceutical options... 3 weeks later it soared 142% on takeover rumors...
Well Dylan just released his #1 5G Takeover Target right here >>>
Sponsored
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment